Posaconazole
pharmaceutical drug
Posaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication.
It was approved for medical use in the European Union in October 2005, and in the United States in September 2006. It is available as a generic medication.
Medical uses
Posaconazole is used to treat invasive Aspergillus and Candida infections. It is also used for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory to other drugs such as itraconazole and fluconazole.
Clinical evidence of efficacy in treatment of invasive disease caused by Fusarium species (fusariosis) is limited.
Intravenous administration appears to be helpful in a mouse model of naegleriasis and the drug kills Acanthamoeba castellanii cysts in vitro.
It has been used to treat mucormycosis (black fungus disease) caused by Rhizopus mold.
Pharmacology
Mechanism of action
Posaconazole works by disrupting the functions of certain fungal and protozoal membrane-bound enzyme systems. It does this by blocking the synthesis and turnover of the eukaryotic cell membrane component ergosterol via the inhibition of an enzyme known as CYP51.
This brief starts where responsible research should: with the source description of “Posaconazole” as pharmaceutical drug. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the general reference register because the source frames it as pharmaceutical drug. Its deeper value depends on whether names, dates, institutions and citations support that framing.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Aug 18, 2026. The linked authority identifier is Q906453. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2005 and 2006.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Posaconazole”, its source revision and the description used here.
- Expand the search: follow Posaconazole primary sources, Posaconazole archive and Posaconazole research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Posaconazole”?
- Which institution is responsible for the underlying evidence?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Posaconazole” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.